Skip to main content

Table 1 Participants characteristics

From: Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study

Participants 114
Experience in Treatment of PDAC
 < 5 years 13 (11.4%)
 5–10 years 29 (25.4%)
 > 10 years 72 (63.2%)
Scope of practice
 Surgery 99 (86.8%)
  General surgery 84 (73.7%)
  HPB surgery 15 (13.2%)
 Oncology 15 (13.2%)
  Medical oncology 12 (10.5%)
  Radiation oncology 2 (1.8%)
  Gastroenterology 1 (0.9%)
Origin of participants
 Europe 99 (86.8%)
 Africa 8 (7%)
 Middle East 5 (4.4%)
 South America 2 (1.8%)
 Countries 37